These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. Espinoza S; Manago F; Leo D; Sotnikova TD; Gainetdinov RR CNS Neurol Disord Drug Targets; 2012 May; 11(3):251-63. PubMed ID: 22483291 [TBL] [Abstract][Full Text] [Related]
43. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Jorga KM; Fotteler B; Heizmann P; Zürcher G Eur J Clin Pharmacol; 1998 Jul; 54(5):443-7. PubMed ID: 9754991 [TBL] [Abstract][Full Text] [Related]
45. [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease. Pavese N; Simpson BS; Metta V; Ramlackhansingh A; Chaudhuri KR; Brooks DJ Neuroimage; 2012 Jan; 59(2):1080-4. PubMed ID: 21963917 [TBL] [Abstract][Full Text] [Related]
46. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K; Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133 [TBL] [Abstract][Full Text] [Related]
47. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. Engelbrecht I; Petzer JP; Petzer A Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034 [TBL] [Abstract][Full Text] [Related]
48. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Cropley VL; Fujita M; Bara-Jimenez W; Brown AK; Zhang XY; Sangare J; Herscovitch P; Pike VW; Hallett M; Nathan PJ; Innis RB Psychiatry Res; 2008 Jul; 163(2):171-82. PubMed ID: 18504119 [TBL] [Abstract][Full Text] [Related]
49. Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease. Picco A; Morbelli S; Piccardo A; Arnaldi D; Girtler N; Brugnolo A; Bossert I; Marinelli L; Castaldi A; De Carli F; Campus C; Abbruzzese G; Nobili F Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1062-70. PubMed ID: 25820675 [TBL] [Abstract][Full Text] [Related]
50. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats. Huotari M; Gainetdinov R; Männistö PT Pharmacol Toxicol; 1999 Nov; 85(5):233-8. PubMed ID: 10608486 [TBL] [Abstract][Full Text] [Related]
51. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats. Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242 [TBL] [Abstract][Full Text] [Related]
52. Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions. Park SB; Kwon KY; Lee JY; Im K; Sunwoo JS; Lee KB; Roh H; Ahn MY; Park S; Kim SJ; Oh JS; Kim JS Neurol Sci; 2019 Feb; 40(2):311-317. PubMed ID: 30415448 [TBL] [Abstract][Full Text] [Related]
53. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Polito C; Berti V; Ramat S; Vanzi E; De Cristofaro MT; Pellicanò G; Mungai F; Marini P; Formiconi AR; Sorbi S; Pupi A Neurobiol Aging; 2012 Jan; 33(1):206.e29-39. PubMed ID: 20961661 [TBL] [Abstract][Full Text] [Related]
54. Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography. Hartvig P; Lindner KJ; Tedroff J; Bjurling P; Hörnfelt K; Långström B J Neural Transm Gen Sect; 1992; 87(1):15-22. PubMed ID: 1536715 [TBL] [Abstract][Full Text] [Related]
55. Tolcapone improves cognition and cortical information processing in normal human subjects. Apud JA; Mattay V; Chen J; Kolachana BS; Callicott JH; Rasetti R; Alce G; Iudicello JE; Akbar N; Egan MF; Goldberg TE; Weinberger DR Neuropsychopharmacology; 2007 May; 32(5):1011-20. PubMed ID: 17063156 [TBL] [Abstract][Full Text] [Related]
56. Olfactory dysfunction correlates with putaminal dopamine turnover in early de novo Parkinson's disease. Löhle M; Wolz M; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Storch A J Neural Transm (Vienna); 2020 Jan; 127(1):9-16. PubMed ID: 31863171 [TBL] [Abstract][Full Text] [Related]
60. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys. Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]